Effects of hormone replacement on hemostasis in spontaneous menopause

Menopause

Volumn 8, Issue 2, 2001, Pages 135-140

  Demirol, Aygül ^a   Baykal, Cem ^a   Kirazli, Serafettin ^a   Ayhan, Ali ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Coagulation; Hormone replacement

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CONJUGATED ESTROGEN; FIBRINOGEN; LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROTHROMBIN; THROMBOPLASTIN;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FIBRINOGEN BLOOD LEVEL; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; MENOPAUSE; NORMAL HUMAN; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; THROMBOPLASTIN TIME;

EID: 0035098669     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200103000-00009     Document Type: Article

References (45)

1. Estrogen replacement therapy and cardiovascular protection: Lipid mechanisms are the tip of an iceberg
2. Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey I, Illustrative reference ranges by age, sex, and hormone use
3. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
4. Reduced mortality associated with long-term postmenopausal estrogen therapy
5. Postmenopausal hormone therapy and mortality
6. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement
7. The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women
8. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
9. Surgically confirmed gall bladder disease, venous thromboembolism and breast rumors in relation to postmenopausal estrogen therapy
10. Estrogen replacement therapy and the risk of venous thrombosis
11. Risk of vascular disease in women
12. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
13. Risk of venous thromboembolism in users of hormone replacement therapy
14. Prospective study of exogenous hormones and risk of pulmonary embolism in women
15. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
16. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
17. Classical risk factors and emerging elements in the risk profile for coronary artery disease
18. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
19. Thrombosis and acute coronary artery lesions in sudden ischaemic death
20. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women
21. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors
22. Hemostatic risk factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
23. European consensus development conference on menopause
24. Haemostatic variables and menopausal status: Influence of hormone replacement therapy
25. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women
26. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators
27. The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors
28. Estrogen replacement therapy and the risk of venous thrombosis
29. Inhibition of coronary artery atherosclerosis by 17 beta estradiol in ovariectomized monkeys: Lack of an effect of added progesterone
30. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol fed rabbits
31. Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits: Quantification of cellular proliferation by bromode-oxyuridine
32. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study
33. Population correlates of coagulation factor VII: Importance of age, sex, and menopausal status as determinants of activated factor Vll
34. Effects of hormone replacement therapy in cardiovascular risk factors in postmenopausal women
35. Estrogen replacement therapy and coagulation: Relationship to lipid and lipoprotein changes
36. Effects of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women: A randomized, double-blind, placebo-controlled, crossover study
37. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis: Strong, independent and comprehensive. ECAT Angina Pectoris Study Group
38. Lipoprotein (a), fibrin binding, and plasminogen activation
39. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice
40. Metabolism of apo (a) and apoB100 of lipoprotein(a) in women: Effect of postmenopausal estrogen replacement
41. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy
42. Hormone replacement therapy lowers plasma Lp(a) concentrations: Comparison of cyclic transdermal and continuous estrogen progesterone regimens
43. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women
44. Resistance to activated protein C in healthy women taking oral contraceptives
45. Leiden mutation and the risks for thromboembolic disease: A clinical perspective